1.Epidemiological characteristics of respiratory syncytial virus among inpatients in a children′s hospital in Shenzhen City from 2020 to 2023
Xiaojuan LUO ; Wei WANG ; Zhenmin REN ; Xiaoying FU ; Yunsheng CHEN ; Wenjian WANG ; Yanmin BAO ; Yuejie ZHENG ; Ke CAO ; Jiehua CHEN
Chinese Journal of Preventive Medicine 2025;59(4):484-489
This study analyzed the epidemiological characteristics and trends of respiratory syncytial virus (RSV) infections among inpatients with acute respiratory infections (ARI) in a children′s hospital in Shenzhen City inpatients from 2020 to 2023. From January 2020 to December 2023, multiple reverse transcription polymerase chain reaction (RT-PCR) combined with capillary electrophoresis fragment analysis technology was used to detect the nucleic acids of 12 respiratory pathogens, including RSV, in hospitalized children diagnosed with ARI. The patients were divided into six age groups: 0 to <6 months, 6 months to <1 year, 1 to <2 years, 2 to <5 years, 5 to <10 years, and 10 to <18 years. A total of 53 033 children were tested, including 6 830 RSV positive cases, with an overall positivity rate of 12.88%. The annual RSV positivity rates from 2020 to 2023 were 20.04%, 16.18%, 4.89%, and 13.33%, respectively, with statistically significant differences between the years ( χ2=1 185.994, P<0.001). The positive rate of RSV detection decreased with increasing age across all years (all P trend<0.05). From 2020 to 2023, the proportion of RSV-positive cases aged 2 to 5 years and older showed an increasing trend ( P trend<0.001 for all years). Compared to 2023, the median age of RSV-infected children was lower in 2020 ( Z=7.826, P<0.001) and 2021 ( Z=6.106, P<0.001). The proportion of severe infections requiring ICU admission did not change significantly across all years ( χ2=0.179, P=0.981). The RSV epidemic season in 2020 mainly occurred during 28-43 weeks, and in 2021, it spanned from 22-43 weeks. However, in 2022, the season was delayed until the 49th week and lasted for three weeks. In 2023, the seasonal epidemic appeared earlier, starting in the 14th week and lasting for 28 weeks. From 2020 to 2023, the rate of RSV co-infections with other pathogens (mycoplasma pneumoniae, human parainfluenza virus, human bocavirus, human coronavirus, human metapneumovirus, and influenza A) significantly increased (all P trend<0.01). In conclusion, the epidemiological characteristics of RSV infections in Shenzhen Children′s Hospital changed from 2020 to 2023. In 2022, there were only delayed, low-intensity and short-lived seasonal epidemics. However, in 2023, there was an earlier and prolonged epidemic, with increased infections in children aged 2 to 5 years and older and a rise in co-infections, while the proportion of severe infections requiring ICU admission remained unchanged.
2.A multicentre retrospective study of house dust mite allergen preparation treating multi-sensitized allergic rhinitis patients
Zhouxian PAN ; Shengyang YAO ; Yongshi YANG ; Lisha LI ; Ruonan CHAI ; Wenchao GUAN ; Xiaoshang LOU ; Chuanhe LIU ; Li SHA ; Yanmin BAO ; Shijie ZHUANG ; Yin WANG ; Kai GUAN ; Rongfei ZHU
Chinese Journal of Preventive Medicine 2025;59(6):834-843
Objective:To investigate, for multi-sensitized allergic rhinitis (AR) patients allergic to dust mites combined with other allergens (pollen, mold, animal dander, etc.), whether the single dust mite subcutaneous immunotherapy (SCIT) can improve the specific symptoms caused by other allergens in the patients, and to analyze the relationship between the effectiveness of symptom improvement in these patients and the type, quantity and severity of the allergens.Methods:A multicenter retrospective study was conducted to collect mul-sensitized AR patients from allergy or respiratory departments of 5 hospitals who received house dust mite allergen preparation SCIT for 12 to 36 months and met other inclusion and exclusion criteria from February to July 2024. General clinical data were collected and the perennial or seasonal symptoms before and after treatment were evaluated with visual analogue scale (VAS) to assess whether there was an perennial or allergen-specific symptom improvement (VAS score decrease ≥30%), by which the patients were divided into effective group and ineffective. R software was used to analyze the differences between groups by using Fisher′s exact test and Mann-Whitney U test. Results:A total of 62 patients were enrolled, and the treatment were effective in 39 of them, with an effective rate of 62.9%. For allergen-specific symptoms, the median age of the effective group was higher than that of the ineffective group (12 years old vs. 8 years old, P=0.039), and the effective rate in dust mite specific immunoglobin E (sIgE) grade ≤5 group was higher than that in sIgE grade >5 group (81.6% vs. 45.5%, P=0.008), and the effective rate of mold sIgE grade ≤2 group was higher than that of sIgE grade >2 group (83.3% vs. 28.6%, P=0.045), and there was no statistically significant correlation between the other allergen grades and the effective rate ( P>0.05). For perennial symptoms, the effective rate in the mold grade ≤2 group was higher than that in the sIgE grade >2 group (91.3% vs. 28.6%, P=0.010), and there was no statistically significant correlation between the other allergen grades and the effective rate ( P>0.05). There was no significant correlation between the treatment effectiveness of perennial or allergen-specific symptoms and the number of combined allergens, the grade of skin test, and the difference between the grade of combined allergens and that of dust mites ( P>0.05). Conclusion:Among the patients with multi-sensitized AR allergic to dust mites included in this study, single dust mite SCIT is effective in some of them, and for allergen-specific symptoms, the effective group was elder, and dust mite sIgE grade 6 and mold sIgE grade ≥2 was related to the low effective rate of SCIT. The present results are insufficient for selecting single or multiple AIT in any type of multi-sensitized patients.
3.Epidemiological characteristics of respiratory syncytial virus among inpatients in a children′s hospital in Shenzhen City from 2020 to 2023
Xiaojuan LUO ; Wei WANG ; Zhenmin REN ; Xiaoying FU ; Yunsheng CHEN ; Wenjian WANG ; Yanmin BAO ; Yuejie ZHENG ; Ke CAO ; Jiehua CHEN
Chinese Journal of Preventive Medicine 2025;59(4):484-489
This study analyzed the epidemiological characteristics and trends of respiratory syncytial virus (RSV) infections among inpatients with acute respiratory infections (ARI) in a children′s hospital in Shenzhen City inpatients from 2020 to 2023. From January 2020 to December 2023, multiple reverse transcription polymerase chain reaction (RT-PCR) combined with capillary electrophoresis fragment analysis technology was used to detect the nucleic acids of 12 respiratory pathogens, including RSV, in hospitalized children diagnosed with ARI. The patients were divided into six age groups: 0 to <6 months, 6 months to <1 year, 1 to <2 years, 2 to <5 years, 5 to <10 years, and 10 to <18 years. A total of 53 033 children were tested, including 6 830 RSV positive cases, with an overall positivity rate of 12.88%. The annual RSV positivity rates from 2020 to 2023 were 20.04%, 16.18%, 4.89%, and 13.33%, respectively, with statistically significant differences between the years ( χ2=1 185.994, P<0.001). The positive rate of RSV detection decreased with increasing age across all years (all P trend<0.05). From 2020 to 2023, the proportion of RSV-positive cases aged 2 to 5 years and older showed an increasing trend ( P trend<0.001 for all years). Compared to 2023, the median age of RSV-infected children was lower in 2020 ( Z=7.826, P<0.001) and 2021 ( Z=6.106, P<0.001). The proportion of severe infections requiring ICU admission did not change significantly across all years ( χ2=0.179, P=0.981). The RSV epidemic season in 2020 mainly occurred during 28-43 weeks, and in 2021, it spanned from 22-43 weeks. However, in 2022, the season was delayed until the 49th week and lasted for three weeks. In 2023, the seasonal epidemic appeared earlier, starting in the 14th week and lasting for 28 weeks. From 2020 to 2023, the rate of RSV co-infections with other pathogens (mycoplasma pneumoniae, human parainfluenza virus, human bocavirus, human coronavirus, human metapneumovirus, and influenza A) significantly increased (all P trend<0.01). In conclusion, the epidemiological characteristics of RSV infections in Shenzhen Children′s Hospital changed from 2020 to 2023. In 2022, there were only delayed, low-intensity and short-lived seasonal epidemics. However, in 2023, there was an earlier and prolonged epidemic, with increased infections in children aged 2 to 5 years and older and a rise in co-infections, while the proportion of severe infections requiring ICU admission remained unchanged.
4.A multicentre retrospective study of house dust mite allergen preparation treating multi-sensitized allergic rhinitis patients
Zhouxian PAN ; Shengyang YAO ; Yongshi YANG ; Lisha LI ; Ruonan CHAI ; Wenchao GUAN ; Xiaoshang LOU ; Chuanhe LIU ; Li SHA ; Yanmin BAO ; Shijie ZHUANG ; Yin WANG ; Kai GUAN ; Rongfei ZHU
Chinese Journal of Preventive Medicine 2025;59(6):834-843
Objective:To investigate, for multi-sensitized allergic rhinitis (AR) patients allergic to dust mites combined with other allergens (pollen, mold, animal dander, etc.), whether the single dust mite subcutaneous immunotherapy (SCIT) can improve the specific symptoms caused by other allergens in the patients, and to analyze the relationship between the effectiveness of symptom improvement in these patients and the type, quantity and severity of the allergens.Methods:A multicenter retrospective study was conducted to collect mul-sensitized AR patients from allergy or respiratory departments of 5 hospitals who received house dust mite allergen preparation SCIT for 12 to 36 months and met other inclusion and exclusion criteria from February to July 2024. General clinical data were collected and the perennial or seasonal symptoms before and after treatment were evaluated with visual analogue scale (VAS) to assess whether there was an perennial or allergen-specific symptom improvement (VAS score decrease ≥30%), by which the patients were divided into effective group and ineffective. R software was used to analyze the differences between groups by using Fisher′s exact test and Mann-Whitney U test. Results:A total of 62 patients were enrolled, and the treatment were effective in 39 of them, with an effective rate of 62.9%. For allergen-specific symptoms, the median age of the effective group was higher than that of the ineffective group (12 years old vs. 8 years old, P=0.039), and the effective rate in dust mite specific immunoglobin E (sIgE) grade ≤5 group was higher than that in sIgE grade >5 group (81.6% vs. 45.5%, P=0.008), and the effective rate of mold sIgE grade ≤2 group was higher than that of sIgE grade >2 group (83.3% vs. 28.6%, P=0.045), and there was no statistically significant correlation between the other allergen grades and the effective rate ( P>0.05). For perennial symptoms, the effective rate in the mold grade ≤2 group was higher than that in the sIgE grade >2 group (91.3% vs. 28.6%, P=0.010), and there was no statistically significant correlation between the other allergen grades and the effective rate ( P>0.05). There was no significant correlation between the treatment effectiveness of perennial or allergen-specific symptoms and the number of combined allergens, the grade of skin test, and the difference between the grade of combined allergens and that of dust mites ( P>0.05). Conclusion:Among the patients with multi-sensitized AR allergic to dust mites included in this study, single dust mite SCIT is effective in some of them, and for allergen-specific symptoms, the effective group was elder, and dust mite sIgE grade 6 and mold sIgE grade ≥2 was related to the low effective rate of SCIT. The present results are insufficient for selecting single or multiple AIT in any type of multi-sensitized patients.
5.Interpretation of diagnosis and management of asthma in children aged 5 years and younger in Global Initiative for Asthma (GINA) 2025 Update
Peng HAN ; Yanmin BAO ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2025;40(8):589-594
The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.
6.Interpretation of anti-inflammatory reliever and maintenance and reliever therapy for children in Global Initiative for Asthma (GINA) 2025 Update
Peng HAN ; Yuejie ZHENG ; Yanmin BAO ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2025;40(11):817-820
The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.
7.Interpretation of diagnosis and management of asthma in children aged 5 years and younger in Global Initiative for Asthma (GINA) 2025 Update
Peng HAN ; Yanmin BAO ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2025;40(8):589-594
The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.
8.Interpretation of anti-inflammatory reliever and maintenance and reliever therapy for children in Global Initiative for Asthma (GINA) 2025 Update
Peng HAN ; Yuejie ZHENG ; Yanmin BAO ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2025;40(11):817-820
The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.
9.Application of near infrared responsive hydrogels in tissue engineering
Jing XU ; Huixin LYU ; Xin BAO ; Yi ZHANG ; Yihan WANG ; Yanmin ZHOU
Chinese Journal of Tissue Engineering Research 2024;28(3):486-492
BACKGROUND:Near infrared responsive hydrogels,have a variety of excellent properties such as high spatial and temporal precision,remote tunability,and safety and non-invasiveness,providing a new direction of exploration for the development of tissue engineering. OBJECTIVE:To summarize the application progress of near infrared responsive hydrogels in the field of tissue engineering in recent years. METHODS:The literature search was performed on PubMed and CNKI databases.The keywords were"near infrared responsive hydrogels,tissue engineering,bone defect,bone repair,bone regeneration,wound healing,wound dressing,angiogenesis"in Chinese and English.The search time limit was from May 2006 to October 2022 and extended for some classical literature.The abstracts and contents of the retrieved literature were analyzed,and the relevant literature was obtained according to inclusion and exclusion criteria.Finally,97 articles were included for review. RESULTS AND CONCLUSION:(1)Near infrared responsive materials are involved in tissue repair by controlling infection and reducing inflammation,promoting angiogenesis,osteoblast differentiation and new bone formation.(2)Near infrared responsive hydrogel can be prepared by constructing a thermosensitive hydrogel with a photothermal effect or by using a photochemical reaction.(3)Near infrared responsive hydrogels as wound dressings perform various functions such as rapid hemostasis,tissue adhesion through polymerization of polymer monomers,antibacterial and anti-inflammatory effects,and promotion of angiopoiesis and epithelial regeneration through the local photothermal effect of photothermal nanomaterials during soft tissue healing and regeneration.(4)Near infrared responsive hydrogels function during bone reconstruction and repair by promoting osteogenic differentiation of mesenchymal stem cells,stimulating the expression of heat shock proteins,and increasing angiogenesis.(5)Near infrared responsive hydrogels present a combination of multiple therapeutic strategies with significant synergistic therapeutic functions and are also being progressively developed for application in other tissue reconstruction and disease treatment scenarios.
10.Clinical analysis of 4 children with cryptogenic organizing pneumonia
Chunyan LIU ; Yanmin BAO ; Yuejie ZHENG
Chinese Journal of Pediatrics 2024;62(3):268-272
Objective:To analyze the clinical features of children with cryptogenic organizing pneumonia (COP) confirmed by pathology.Methods:The clinical manifestations, imaging, pathology, treatment and outcome data of 4 children with COP confirmed by thoracoscopic lung biopsy were retrospectively analyzed, who were hospitalized at Respiratory Department of Shenzhen Children′s Hospital from January 2004 to December 2022.Results:All of the 4 patients were male, the age ranged from 1 year 3 months to 14 years. The time from onset to diagnosis was 3 months to 3 years. The follow-up duration was 6 months to 6 years. All the 4 cases had cough, 2 cases had tachypnea and wheezing, 1 case had expectoration, 1 case had chest pain, 1 case had decreased activity tolerance and weight loss. Rales in 2 cases and hypoxemia in 1 case. Pulmonary high resolution CT showed diffuse distribution, involvement of both lungs in 3 cases, and single lung combined migration in 1 case.Three cases showed ground-glass opacity, consolidation, patchy or fibrous strips, and 1 case presented air bronchogram and "reversed halo sign". All the 4 cases were performed thoracoscopic lung biopsy, and the pathological findings showed cellulose exudate or small nodules filled with granulation tissue or fibroblasts in the alveolar cavity and small airways, and 1 case was Masson corpuscle positive. Three patients achieved remission after glucocorticoid therapy. Spontaneous remission without treatment was seen in 1 patient.Two cases were followed up for 17 months and 6 years, respectively, who had excellent outcome.Conclusions:The manifestations of COP in children include cough, expectoration and chest pain. Infants and young children may have tachypnea and wheezing. The most common chest CT findings are diffuse distribution of ground-glass opacity, patchy and consolidation in both lungs. Diagnosis should depend on pathological examination. The effect of glucocorticoid therapy is good.

Result Analysis
Print
Save
E-mail